title: Clinical outcomes associated with conversion from epoetin alfa to darbepoetin alfa in hospitalized hemodialysis patients.
abstract: OBJECTIVE
  Hemodialysis patients are often hospitalized, during which time they require continuity of care in the inpatient setting. The goal of the present study was to evaluate the clinical outcomes associated with a conversion algorithm from outpatient epoetin alfa to inpatient darbepoetin alfa in hospitalized hemodialysis patients at the St. Elizabeth Health Center.
  
  
  METHODS
  We conducted a retrospective chart review of hemodialysis patient hospital admissions after a therapeutic interchange from epoetin alfa to darbepoetin alfa was implemented at St. Elizabeth Health Center. Chronic hemodialysis patients admitted from December 2002 to October 2003 were identified as part of a therapeutic interchange cohort receiving inpatient darbepoetin alfa after conversion from outpatient epoetin alfa according to the Aranesp package insert during their hospitalization. After discharge, these patients were returned to their preadmission outpatient epoetin alfa dosages and frequencies. Patients admitted prior to implementation of the therapeutic interchange (January 2002 to April 2002) received epoetin alfa during hospitalization and served as a historical control. Hemoglobin values were recorded prior to hospital admission, at the time of discharge, and 30 days after discharge.
  
  
  RESULTS
  Mean hemoglobin levels declined from preadmission to discharge, in both the interchange and historical cohorts (6.6 and 2.5%, respectively) and rebounded at 30 days after discharge. Using a linear regression model, the only variables significantly associated with the hemoglobin level at discharge were the hemoglobin level before admission and receipt of a blood transfusion.
  
  
  CONCLUSIONS
  An algorithm-based conversion from outpatient epoetin alfa to inpatient darbepoetin alfa for hospitalized chronic hemodialysis patients utilizing the dose conversion table specified in the Aranesp package insert is associated with hemoglobin outcomes similar to inpatient epoetin alfa.
authors.affiliation: Department of Internal Medicine, Youngstown State University, Youngstown, Ohio, USA. esarac2000@yahoo.com
authors.forename: Erdal
authors.initials: E
authors.lastname: Sarac
authors.forename: Anand
authors.initials: A
authors.lastname: Chikyarappa
authors.forename: Brian
authors.initials: B
authors.lastname: Sabol
authors.forename: David
authors.initials: D
authors.lastname: Gemmel
authors.forename: Denise
authors.initials: D
authors.lastname: Globe
authors.forename: Arie
authors.initials: A
authors.lastname: Barlev
authors.forename: Paul
authors.initials: P
authors.lastname: Audhya
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000465:Algorithms; D000068256:Darbepoetin alfa; D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D005260:Female; D006304:Health Status; D006397:Hematinics / Q000008:administration & dosage*; D006454:Hemoglobins / Q000187:drug effects*; D006760:Hospitalization; D006801:Humans; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins; D006435:Renal Dialysis; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D006397:Hematinics; D006454:Hemoglobins; D011994:Recombinant Proteins; D004921:Erythropoietin; D000068256:Darbepoetin alfa; D000068817:Epoetin Alfa